Canadian Partnership for Quality Radiotherapy Technical Quality Control Guidelines for Brachytherapy Remote Afterloaders

A guidance document on behalf of:

Canadian Association of Radiation Oncology

Canadian Organization of Medical Physicists

Canadian Association of Medical Radiation Technologists

Canadian Partnership Against Cancer

June 29, 2015

BRA.2015.06.02

www.cpqr.ca



Disclaimer All information contained in this document is intended to be used at the discretion of each individual centre to help guide quality and safety program improvement. There are no legal standards supporting this document; specific federal or provincial regulations and licence conditions take precedence over the content of this document. As a living document, the information contained within this document is subject to change at any time without notice. In no event shall the Canadian Partnership for Quality Radiotherapy (CPQR) or its partner associations, the Canadian Association of Radiation Oncology (CARO), the Canadian

Organization of Medical Physicists (COMP), and the Canadian Association of Medical Radiation Technologists (CAMRT), be liable for any damages, losses, expenses, or costs whatsoever arising in

connection with the use of this document.

Expert Reviewer

Normand Frenière

CIUSSS de la Mauricie-et-du-Centre-du-Québec – CSSS de Trois-Rivières – CHAU régional, Trois-Rivières, Quebec

External Validation Centres

BC Cancer Agency – Vancouver Centre, Vancouver, British Columbia CIUSSS du Saguenay – Lac-Saint-Jean – Hôpital de Chicoutimi, Chicoutimi, Quebec

Introduction

The Canadian Partnership for Quality Radiotherapy (CPQR) is an alliance amongst the three key national professional organizations involved in the delivery of radiation treatment in Canada: the Canadian Association of Radiation Oncology (CARO), the Canadian Organization of Medical Physicists (COMP), and the Canadian Association of Medical Radiation Technologists (CAMRT). Financial and strategic backing is provided by the federal government through the Canadian Partnership Against Cancer (CPAC), a national resource for advancing cancer prevention and treatment. The mandate of the CPQR is to support the universal availability of high quality and safe radiotherapy for all Canadians through system performance improvement and the development of consensus-based guidelines and indicators to aid in radiation treatment program development and evaluation.

This document contains detailed performance objectives and safety criteria for *Brachytherapy Remote Afterloaders*. Please refer to the overarching document *Technical Quality Control Guidelines for Canadian Radiation Treatment Centres*⁽¹⁾ for a programmatic overview of technical quality control, and a description of how the performance objectives and criteria listed in this document should be interpreted.

System Description

Brachytherapy is the placement of encapsulated radioisotopes or miniaturized x ray tube in, or adjacent to, tissue which has been prescribed a radiation dose. (2-9) This practice offers unique advantages to the management of several treatment sites and has been used to complement or replace external beam radiation therapy since the onset of radiation oncology.

Remote afterloading equipment was developed to reduce, and in many cases eliminate, the radiation exposure to members of the staff. With remote afterloading systems the user does not directly handle the radioactive source and the patient is irradiated in a shielded room with staff operating and monitoring the process remotely.

High dose rate (HDR) refers to treatment dose rates larger than 20 cGy/min. For all HDR remote afterloaders, a single and small (< 1 mm \times 5 mm) radioactive source (mostly Iridium-192, rarely Cobalt-60), laser-welded to a stainless-steel cable, is moved out of the safe by a motor-drive mechanism to step along the prescribed positions (dwell positions) with different irradiation times (dwell times). The user can preselect dwell positions and dwell times at selected positions in a number of applicator lines. The remote afterloader could receive up to two such sources with two independent cables permitting dose delivery in two applicator lines simultaneously. The source strength is approximately 40,000 cGy cm² h-¹ (activity of ~370 GBq) on installation of a new Iridium-192 source, while it is of 23,000 cGy cm² h-¹ (activity of ~74 GBq) for a new Cobalt-60 source. Because Iridium-192 has a relatively short half-life (73.8 days), the sources are usually replaced about every three months. Cobalt-60 has a longer half-life (5.3 years), offering less frequent source replacement to every five years. Typical HDR irradiation times are 5 to 30 minutes, and a treatment course may consist of several fractions.

Another form of HDR treatment is pulsed dose rate (PDR) treatment. With a PDR device, irradiations are given in short "pulses" with the total treatment being given in 48 to 72 hours. The mechanism for PDR units is very similar to that used in HDR units. PDR remote afterloaders also use a single Iridium-192 source attached to a cable. However, the source strength for these units is typically only 10% of the source strength of an Iridium-192 HDR unit.

High-dose rate miniaturized x ray tube remote devices, along with intravascular and cardiovascular brachytherapy remote afterloaders using beta emitting radioactive sources, are beyond the scope of this document.

Various recommendations for brachytherapy quality assurance have been reported in the literature. (10–17) For HDR, "per treatment" tests must be executed prior to each treatment. "Treatment day" tests must be scheduled before treating the first patient of the day. For PDR remote afterloaders where treatments may last several days, "treatment day" tests should be performed prior to the initiation of the treatment.

Related Technical Quality Control Guidelines

In order to comprehensively assess brachytherapy remote afterloader performance, additional guideline tests, as outlined in related CPQR Technical Quality Control (TQC) guidelines must also be completed and documented, as applicable. Related TQC guidelines, available at cpqr.ca, include:

- Safety Systems
- Major Dosimetry Equipment
- Treatment Planning Systems

Test Tables

Table 1: Per Treatment Quality Control Tests

Designator	Test	Performance		
		Action		
Per Treatment (executed prior to each treatment)				
T1	Plan data transfer from treatment planning computer	Accurate		
T2	Plan dwell times adjustment	See note		
Т3	Minimum dwell times	Accurate		
T4	Plan catheters' connection to remote afterloader	Accurate		
T5	Complete source retraction	Functional		
Treatment Day (or Per Treatment for PDR)				
D1	Treatment interrupt	Functional		
D2	Console displays (treatment status indicator) and key switch	Functional		
D3	Date, time, and source strength in treatment unit	Accurate		
D4	Source (and dummy) positional accuracy	2 mm		
D5	Dwell time accuracy	2%		

Notes on Per Treatment Tests

- Plan data imported from a treatment planning system into the treatment console should be verified for source strength, dwell positions, and dwell times. In case of many dwell positions, the verification of a sub-set of positions is acceptable. For a plan already present in the treatment console, the same verification should be made to assure proper plan selection.
- Plan dwell times adjustment by the treatment console for the treatment date should be verified (by an independent calculation: hand calculation, decay factor chart, or software calculation). Action level will depend on the treatment console decay frequency and time resolution; express in percentage of difference and/or in second.
- Minimum dwell time should be verified against the device driven limits. Those limits should take into account both the effect of transit dose and positioning reproducibility. Some remote afterloader systems might have a positioning reproducibility dependence on dwell time.

- T4 Catheters/applicators connections to remote afterloader indexer channels must match plan.
- T5 Survey the treatment room and patient to ensure that source has been completely retracted.

Notes on Treatment Day (or Per Treatment for PDR) Tests

- D1 During source exposure, verify that the non-emergency interrupt button (if equipped) retracts the source to its safe and shielded position.
- On the treatment console, displays should be verified. At minimum, treatment status indicators should be verified by exposing a source. Indicators could be visual and audible. When a treatment key is available, its deactivation should prevent source exposition.
- D3 Remote afterloader console date and time are properly set. Decayed source strength is accurate compared to an independent calculation (hand calculation, decay factor chart or software calculation), taking into account treatment console decay frequency.
- D4 Verify accuracy of source drive mechanism positioning. A visual inspection with a camera is acceptable. Apply also to dummy drive mechanism if used to measure catheter length.
- D5 Comparison of dwell time accuracy with external standard such as a stopwatch. The dwell time used should be sufficiently long such that errors in the measurement of the time (e.g., reaction time of the observer) are less than 1%.

Table 2: Quarterly Quality Control Tests

Designator	Test	Performance		
		Action		
Quarterly (or at source replacement)				
Q1	Mechanical integrity of applicators, guide tubes, connectors	Functional		
Q2	Internal battery power supply (power failure recovery)	Functional		
Q3	Source/dummy interlocks	Functional		
Q4	Dummy positional accuracy	3 mm (1 mm see note)		
Q5	Radiological source positional accuracy	1 mm		

Q6	Source strength calibration	5%
Q7	Source homogeneity	Baseline
Q8	Records	Complete

Notes on Quarterly Tests

- Q1 Verify the applicators, guide tubes, and connectors are exempt of damage (excessive wear, kinks, etc.).
- Q2 The configuration of this test will depend on the design of the facility and equipment. Safety is the concern and tests should be designed accordingly. The first objective is to verify that the equipment safely retracts the source wire after a power failure. The second objective is to verify that the equipment properly records treatment delivered before power failure and permits to resume the treatment after power recovery.
- Q3 Verify functionality of remote afterloader interlocks related to source and dummy wires. This includes incorrect connection of applicator to transfer guide tube, incorrect connection of transfer guide tube to remote afterloader, and obstruction.
- Q4 Verify accuracy of dummy drive mechanism positioning. The purpose is to assure proper obstruction detection by assuring no false positive or false negative obstruction. If dummy drive mechanism is used to measure catheter length, then the action level should be lowered to 1 mm.
- Q5 Accuracy of source drive mechanism to be verified. Autoradiographs or ion-chamber measurements could be used. If visual checks with in-room cameras are to be used, source positioning in the cable construction should be verified independently.
- Comparison of measured source strength with manufacturer supplied value. On installation of a new source, source strength must be measured using calibrated re-entrant chamber and electrometer traceable to a national standards laboratory. The re-entrant chamber and electrometer should have been calibrated within the last 2 years. Measured source strength should be used for planning and treatment purposes. Discrepancies greater than 5% between the measured and the manufacturer's supplied source strengths must be investigated. Stability of re-entrant chamber should be verified prior to use. A second qualified medical physicist should perform a check of the calibration.

- Q7 Visual check on film that the radioactive material is evenly distributed in the encapsulated source. Most important for sources composed of multiple source pellets.
- Q8 Documentation relating to the daily quality control checks, preventive maintenance, service calls, and subsequent checks must be complete, legible, and the operator identified.


Table 3: Annual Quality Control Tests

Designator	Test	Performance		
		Action		
Annually				
A1	Hand crank operation	Functional		
A2	Leakage radiation	Baseline		
А3	Multi-channel indexer function	Functional		
A4	Dwell time accuracy	1%		
A5	Timer linearity	1%		
A6	Transit time/transit dose reproducibility	Baseline		
A7	Dosimetric length of applicators and guide tubes	1 mm		
A8	Applicators and templates dimensions	Baseline		
A9	Shield integrity of shielded applicators	Baseline		
A10	X ray marker positional accuracy	1 mm		
A11	Review emergency response procedures	Complete		
A12	Independent quality control review	Complete		
A13	PDR sequencing (for PDR only)	Functional		

Notes on Annual Tests

- A1 Manual emergency hand crank should be verified with manufacturer service engineer.

 It is desirable that each person responsible to operate the hand crank, in an emergency situation, practices its operation annually when a dummy wire replaces the source wire.
- A2 Monitor leakage radiation to check afterloader's safe integrity.



Acknowledgements

We would like to thank the many people who participated in the production of this guideline. These include: Michelle Nielsen and Marie-Joelle Bertrand (associate editors); the Quality Assurance and Radiation Safety Advisory Committee; the COMP Board of Directors, Erika Brown and the CPQR Steering Committee, and all individuals that submitted comments during the community review of this guideline.

References

- Canadian Partnership for Quality Radiotherapy. Technical quality control guidelines for Canadian radiation treatment centres. 2016 May 1. Available from: http://www.cpgr.ca/programs/technical-quality-control
- 2. Erickson BA, Demanes D, Ibbott GS, Hayes JK, Hsu IJ, Morris DE, Rabinovitch RA, Tward JD, Rosenthal SA. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 2011 Mar 1;79(3):641–49.
- 3. Glasgow GP. Brachytherapy. In: Van Dyk J, editor. The modern technology of radiation oncology: a compendium for medical physicists and radiation oncologists. Madison (WI): Medical Physics Publishing; 1999. p. 695–752. ISBN 978-0944838228.
- 4. Glasgow GP, Bourland JP, Grigsby PW, Meli JA, Weaver KA. Report of Task Group 41: remote afterloading technology. New York: American Institute of Physics; 1993. Available from: https://www.aapm.org/pubs/reports/rpt 41.pdf
- 5. Kubo HD, Glasgow GP, Pethel TD, Thomadsen BR, Williamson BF. High dose-rate brachytherapy treatment delivery: report of the AAPM Radiation Therapy Committee Task Group No. 59. Med. Phys. 1998 Jan 28;25(4):375–403.
- 6. Nath R, Anderson LL, Meli JA, Olch AJ, Stitt JA, Williamson JF. Code of practice for brachytherapy physics: report of the AAPM Radiation Therapy Committee Task Group No. 56. American Association of Physicists in Medicine. Med. Phys. 1997 Aug 4;24(10):1557–98.
- 7. Podgorsak EB, editor. Radiation oncology physics: a handbook for teachers and students. Vienna, Austria. International Atomic Energy Agency. 2005 Jul [cited 2016 Jul 19]. Available from: http://www-pub.iaea.org/mtcd/publications/pdf/pub1196 web.pdf
- 8. Purdy JA, editor. Medical Physics Monograph. Advances in radiation oncology physics: dosimetry, treatment planning, and brachytherapy, vol 19. Woodbury (NY): American Institute of Physics; 1992. ISBN 978-1563960543.

- 9. Thomadsen BR, Rivard MR, Butler W, editors. Medical physics monograph. 2nd ed. Vol. 31. Brachytherapy Physics. Madison (WI): Medical Physics Publishing; 2005. ISBN 978-1930524248.
- American College of Radiology. ACR technical standard for the performance of high-dose-rate brachytherapy physics, technical standard, external beam physics. Reston (VI): American College of Radiology; 2010. Available from: http://www.acr.org/~/media/EF9F4CCED3C5426B915BC2C91974CE51.pdf
- 11. Bastin KT, Podgorsak MS, Thomadsen BR. The transit dose component of high dose-rate brachytherapy: direct measurements and clinical implications. Int. J. Radiat. Oncol. Biol. Phys. 26. 1993. Jul 15;695–702. Available from: http://dx.doi.org/10.1016/0360-3016(93)90291-3
- 12. DeWerd L, Jursinic P, Kitchen R, Thomadsen B. Quality assurance tool for high dose rate brachytherapy. Med. Phys. 1995; 22(4):435–40. Available from: http://dx.doi.org/10.1118/1.597469
- 13. Kutcher GJ, Coia L, Gillin M, Hanson WF, Leibel S, Morton RJ, Palta JR, Purdy JA, Reinstein LE, Svensson GK, et al. Comprehensive QA for radiation oncology: report of AAPM Radiation Therapy Committee Task Group 40. Med. Phys. 1994;21(4):581–618. Available from: http://dx.doi.org/10.1118/1.597316
- 14. Nag S, Dobelbower R, Glasgow G, Gustafson G, Syed N, Thomadsen B, Williamson JF. Inter-society standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACRO. Crit. Rev. Oncol. Hematol. 2003 Oct;48(1):1–17. Available from: http://dx.doi.org/10.1016/S1040-8428(03)00026-X
- 15. Rickey DW, Sasaki D, Bews J. A quality assurance tool for high dose rate brachytherapy. Med. Phys. 2010;37(6):2525–32. Available from: http://dx.doi.org/10.1118/1.3425786
- 16. Venselaar J, Pérez-Calatayud, J, editors. A practical guide to quality control of brachytherapy equipment, European Guidelines for Quality Assurance in Radiotherapy booklet no. 8. Brussels, Belgium: ESTRO; 2004. ISBN 90-804532-8.
- 17. Zuofeng L, Mitchell TP, Palta JR, Liu C. A quality assurance test tool for high dose-rate remote afterloading brachytherapy units. Med. Phys. 1998;25(2):232–5. Available from: http://dx.doi.org/10.1118/1.598185